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Severe acute respiratory 
syndrome coronavirus 2
Coronaviruses are a large family of viruses that can cause a variety of diseases in humans. Some 
coronaviruses cause only mild illnesses like the common cold. While, some coronaviruses such 
as SARS-CoV (SARS-associated coronavirus) and Middle East respiratory syndrome coronavirus 
(MERS-CoV) have, in recent years, been able to cause severe respiratory involvement (pneumonia), 
leading to death in several patients. By identifying the genomic sequence of the new human 
coronavirus SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) it has been revealed 
that it belongs to the beta coronavirus genus. COVID-19 appears to be transmitted by a mechanism 
similar to the influenza virus via person to person, sneezing coughing, or contact with the secretions 
of infected patients. Early symptoms of these respiratory viruses include fever, cough, and shortness 
of breath, with an incubation period of 2-14 days. SARS-CoV-2 is an acute respiratory disease 
that initially causes lung damage. SARS-CoV-2 can affect other organs, including the kidneys. 
Kidney damage may be caused by alterations that occur during coronavirus infection. It seems that 
low-oxygen delivery to tissues like the kidney in the setting of this disease may lead to ischemic 
damage of the kidney. Considering the importance of the kidneys, as one, this review study aimed 
to investigate the effect of the new coronavirus on the kidneys and its role in the development of 
renal failure. 
ABSTRACT
Implication for health policy/practice/research/medical education:
Acute kidney injury in patients with COVID-19 can be the result of specific pathogenic conditions, including cytokine release syndrome.
Please cite this paper as: Aleebrahim-Dehkordi E, Reyhanian A, Saberianpour Sh, Hasanpour-Dehkordi  A. Acute kidney injury in COVID-19; 
a review on current knowledge. J Nephropathol. 2020;9(4):e31. DOI: 10.34172/jnp.2020.31.
Introduction 
In early December 2019, a number of pneumonia cases of 
unknown origin emerged in Wuhan, China. Most of these 
patients had exposure to the Huanan Seafood Wholesale 
Market selling many species of live animals. The disease 
had fast spread to other parts of China, and globally to 
many countries (1). With rapid spread of the disease in 
China and then all over the world, the new coronavirus 
scientifically named SARS-CoV-2 (severe acute respiratory 
syndrome coronavirus 2) and the resulting illness known 
as COVID-19 caused a great deal of anxiety and panic 
worldwide.
Rapidly increasing number of COVID-19 cases and 
subsequent deaths globally spurred WHO to declare a 
Public Health Emergency of International Concern on 
January 30, 2020, which was upgraded to the declaration 
of Pandemic on March 11, 2020 (2,3). Phylogenetically, 
the virus belongs to the same genus  as the severe acute 
respiratory syndrome coronavirus (SARS-CoV) and 
Middle East respiratory syndrome coronavirus (MERS-
CoV) (4,5). COVID-19 is a respiratory disease; therefore, 
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fever, cough, and shortness of breath. The incubation 
period of COVID19 seems to be 2-14 days (6).  The 
severity of COVID-19 ranges from no symptoms to severe 
or sometimes fatal disease. According to reports, 81% of 
COVID-19 patients in China had mild symptoms while 
others had severe or critical involvement (7-9).  Of 41 
confirmed cases of SARS-CoV-2 infection admitted to 
Wuhan, China hospital, it was found that fever (98%), 
cough (76%), shortness of breath (55%), and muscle 
pain and fatigue (44%) were the most common clinical 
symptoms (3). In addition, symptoms of the upper 
respiratory tract such as sore throat and runny nose to a 
lesser degree were observed in patients with COVID-19. 
Unlike SARS-CoV, gastrointestinal symptoms such as 
diarrhea are rarely seen in patients with SARS-CoV-2 (3,7). 
According to a recent study, the main route of transmission 
of SARS-CoV2 (COVID-19) is through inhalation of 
respiratory droplets and close contact with the infected 
patients (3). The highest rate of virus transmission is seen 
when the person has clinical symptoms (10). However, 
some patients are capable to transmit the infection to 
others before the appearance of clinical symptoms. (10). 
Lungs are the primary organ affected by COVID-19; 
however, in severe cases, other organs can also be affected. 
Other organ dysfunctions are also seen in people severely 
affected by COVID-19. This organ damage is not always 
directly caused by infection but may be caused by the 
body’s response to infection. Some admitted patients with 
COVID19 also have acute kidney damage, sometimes 
requiring hemodialysis. The damage has also occurred 
in other human coronaviruses  including SARS-CoV 
and MERS-CoV (11-13). Some viral diseases (including 
human chiropractors) can affect the kidney function 
during severe infections (14). Considering the importance 
of the kidney, this review study aimed to investigate the 
effect of the new coronavirus (SARS-CoV2) on the kidney 
and its role in the development of renal failure. 
Acute kidney injury
Acute kidney injury (AKI) is a condition during which 
glomerular filtration rate (GFR) is suddenly reduced with 
retaining nitrogenous wastes. It also disturbs extracellular 
fluid volume, electrolytes, and homeostasis in the body. 
In general, AKI is classified into five subgroups, including 
classifications of RIFLE (Risk, Injury, Failure, Loss, and 
End-stage renal failure), each with specific clinical and 
para-clinical indicators (15-17).
Kidney damage in SARS-CoV2 infection
In addition to the alveolar cells in the lungs, ACE2 
(angiotensin-converting enzyme 2) has been reported in 
other organs including the kidney (18). Both ACE2 and 
dipeptidyl peptidase-4 are expressed on renal tubular cells 
that help to bind SARS-CoV and MERS-CoV, respectively 
(19). Additionally, viral RNA has been detected in kidney 
tissue and urine in both infections (20). ACE2 receptors 
mediate entry of some types of coronaviruses into the 
human body cells. ACE2 receptors play an important 
role in the virus entrance and may cause target cells to 
become susceptible to COVID-19 infection  (21,22). 
The angiotensinogen protein is converted to angiotensin 
I by the renin hormone (released from the kidney) and 
subsequently to angiotensin II by angiotensin-converting 
enzyme (23-26), which is most commonly found in lung 
capillaries (22,27-32). The ACE2 is a receptor for SARS-
CoV and the human respiratory tract virus NL63 (34, 35). 
Previous studies have shown a positive association between 
ACE2 expression and SARS-CoV infection in vitro. Several 
variants of the ACE2 gene can reduce the association 
between ACE2 and S protein in SARS-CoV or NL63 
(32,34,36). Therefore, the expression level and expression 
pattern of the human ACE2 gene in different tissues may 
be crucial for the sensitivity, symptoms, and outcome of 
SARS-CoV-2 infection (36). It has been revealed that 
ACE2 is highly expressed in the brush border of proximal 
tubular cells and, to a lesser extent, in podocytes, but not in 
glomerular endothelial and mesangial cells (18). However, 
at the time of the outbreak of SARS, only 6% of SARS-
CoV-infected subjects experienced AKI (37). Although 
AKI is an uncommon feature of SARS viral disease, it has 
been identified as one of the fatal complications of this 
infection According to previous studies on SARS-CoV 
and MERS-CoV infections, AKI has developed in 5% to 
15% cases with high mortality rate (60%–90%). Early 
reports suggested a lower incidence (3%–9%) of AKI in 
those with COVID-19 (8,38). To specify that  whether 
AKI was induced by active SARS replication in tubular 
cells, Lai and colleagues investigated the presence of SARS 
viral particles using electron transmission microscopy in 
renal specimens of postmortem SARS patients with AKI. 
They found that SARS-CoV was not detected in any of 
analyzed patients and assumed that kidney dysfunction is 
probably related to multiple organ failure  (39). Another 
study reported the expression and distribution of ACE2 
and TMPRSSs genes in the kidney cell components, 
and found that podocytes and proximal straight tubular 
cells were  potential host cells targeted by SARS-CoV-2, 
resulting in AKI caused by the virus-induced cytopathic 
effect  (40). During fatal pneumonia, AKI  patients may 
be affected by synergistic assaults from the virus-induced 
cytopathic effect and systemic inflammatory response, 
especially in severe  and critical cases with positive viral 
RNA in blood samples and massive  proteinuria (40). 
Concerning the new coronavirus (SARS-CoV-2), studies 
have shown that  the human kidney is a specific target 
for SARS-CoV-2 infection (41). Researchers evaluated 
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the viral nucleocapsid protein in situ in the kidney 
post-mortem and found that SARS-CoV-2 antigens 
accumulated in kidney tubules, suggesting that SARS-
CoV-2 infects the human kidney directly and therefore 
induces AKI and contributes to viral spreading in the 
body  (41). 
Clinical and laboratory findings in COVID-19 patients 
with renal impairment 
Proteinuria, hematuria, inflammation and edema
Proteinuria is one of the abnormal urinary results and 
is one of the diagnostic tests  (42-44). A recent study 
conducted on 59 patients with COVID-19 found that 
34% of patients developed massive albuminuria on the 
first day of admission, and 63% developed proteinuria 
during their stay in hospital (32). Reports provided by CT 
scan of the kidneys showed reduced density, suggestive of 
swelling and edema (45). Furthermore, subjects infected 
with SARS-CoV-2 seem to be affected by AKI more 
frequently than subjects infected with SARS-CoV (45). 
Blood urea nitrogen was elevated in 27% overall and in 
two-thirds of patients who died (38). Recently, Cheng 
et al reported that amongst hospitalized patients with 
COVID-19, 44% had proteinuria and hematuria and 
26.7% had hematuria on admission. The prevalence 
rates of blood urea and serum creatinine were 14.1% and 
15.5%, respectively (38).
Sepsis 
Sepsis, as the host systemic inflammatory response to 
infection, occurs after the invasion of microbial pathogens 
into the blood stream (46). Sepsis is an extreme response 
to infection that may cause organs failure too. Sepsis 
is among the principal complications and one of the 
leading causes of death in patients with novel coronavirus 
pneumonia (severe acute respiratory syndrome 
coronavirus 2). A cytokine storm cascade following the 
viral infection is the principal cause of sepsis (46,47). 
Based on the first clinical observations, most patients with 
novel coronavirus pneumonia showed enhancement  of 
pro-inflammatory cytokines, such as tumor necrosis factor 
alpha (TNF-α), interleukin 6 (IL-6), and, interferon 
gamma (IFN-γ), with the specifications of cytokine storm 
(47). It is thought that sepsis is due to unregulatation of 
pro-inflammatory mediators forming a cytokine storm. In 
this condition, a lot of cytokines, such as interleukin 12 
(IL-12), IL-6, interleukin-1 (IL-1), TNF-α, IFN-γ, and 
interferon beta (IFN-β)  are quickly produced in body 
liquids after the body is infected (48). IFN-β induces 
the phosphorylation of signal transducer and activator of 
transcription of STAT- proteins through the activation of 
its own receptor, modulating the secretion of cytokines 
that control and adjust inflammation (49). According to 
studies on patients with SARS-CoV2-, it has been found 
that sepsis appears to be one of the mechanisms of kidney 
damage (50).
Cytokine release syndrome
Cytokine release syndrome (CRS) is a systemic 
inflammatory response that can be triggered by a variety 
of factors such as infections (51). Respiratory symptoms 
are common in patients with CRS mild cases, which 
may display tachypnea and cough and progress to acute 
respiratory distress syndrome (ARDS) with hypoxemia, 
and bilateral opacities on chest X-ray and dyspnea 
(52). Patients with severe CRS can also develop kidney 
failure. In severe cases, CRS can be accompanied by 
signs and abnormalities that resemble hemophagocytic 
lymphohistiocytosis or macrophage activation syndrome 
(53). IFN-γ, IL-6, and interleukin 10 (IL-10) are always 
elevated in serum of patients with CRS. IFN-γ secretion 
activates immune cells in patients with CRS, including 
macrophages (54). The activated macrophages generate 
excessive  amounts of additional cytokines such as IL-
10,  IL-6, and TNF-α. TNF-α elicits flu-like symptoms 
such as fever, fatigue, and general malaise. Furthermore, 
it is responsible for the synthesis of acute-phase proteins 
and lung injury (51). IL-6 plays an important role in 
CRS pathophysiology since high levels of IL-6 are seen 
in patients with CRS (55,56(. TNF-α is present in a 
variety of cells, including macrophages, T lymphocytes, 
B lymphocytes, natural killer (NK) cells, neutrophils, 
astrocytes, and endothelial cells (57-59). The most 
important inducer of bacterial lipopolysaccharide (LPS) is 
the production of TNF-α and IFN-γ, which is produced 
by T and NK cells and increases the production of TNF-α 
by macrophages stimulated by bacterial LPS (60). The 
most important physiological action of TNF-α is related 
to the immune system. When the level of TNF-α in 
the blood increases, the contraction of the heart muscle 
and the smooth muscles of the arteries is inhibited, in 
which the blood pressure decreases and thereby sepsis 
occurs (61).  Severe CRS occurs during some infectious 
diseases, including coronavirus infections (62-64). 
Indeed, increasing viral infection in alveolar cells results in 
massive recruitment of immune cells, which produce large 
amount of cytokines, causing multiple-organ failure that 
may occur in SARS-CoV infection (65). In other studies, 
it has been revealed that IFN-γ -induced cytokine cycling 
following SARS-CoV resulted in severe organ damage in 
SARS-CoV patients (66). The exact mechanism of kidney 
involvement in COVID-19 infection is still unclear. 
However, according to some reports, factors such as sepsis 
seem to cause cytokine storm syndrome or direct cellular 
injury due to the virus. 
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Treatment
Due to severe lung injury caused by  SARS-CoV2- 
infection, mortality rate in infected patients requiring 
mechanical ventilation was high (67).  So far, there is 
no specific antiviral drug to cure coronavirus. The main 
solution is supportive care, such as maintaining vital 
signs, regulating oxygen and blood pressure and reducing 
complications such as secondary infections or other 
organs failure, including kidney. Additionally, the current 
treatment of COVID-19 with AKI includes general and 
supportive management and kidney replacement therapy. 
All patients with COVID-19 need to be quarantined. A 
study on a patient with COVID-19 showed that the use of 
lopinavir and ritonavir was effective. However, viral load 
and its probable association with clinical response should 
be kept in mind, since it may be due to the reduction 
in SARS-CoV-2 load. To prove the direct impact  of 
lopinavir/ritonavir, more trials should be executed during 
treatment with COVID-19 (68). Lopinavir and ritonavir 
are both antiviral drugs that are classified as protease 
inhibitors. Both of them block the ability of HIV to bind 
to healthy cells and are often used in combination therapy 
to treat AIDS (69). Recent studies have shown that viral 
polymerase may be a good template for drug design of 
new antivirus to prevent replication of coronavirus (70). 
Chloroquine phosphate is another drug whose results 
have been well demonstrated against new coronavirus 
pneumonia in clinical trials in China. It is used to 
prevent and treat malaria and  as an anti-inflammatory 
agent for the treatment of rheumatoid arthritis and lupus 
erythematosus (71). Results on the efficacy of remdesivir 
on a patient with COVID-19 in China was hopeful 
(45).  Remdesivir is an antiviral drug from the family of 
nucleoside analogs, which was developed to treat the Ebola 
virus (72),  however, it has been shown to have antiviral 
activity against other single-stranded RNA viruses, such 
as coronaviruses (including SARS-CoV and MERS-CoV) 
(73). 
Treatments targeted cytokine storm like Actemra, 
hemoperfusion and other anti-inflammatory agents play 
an important role in treatment COVID19 patients, 
measurement of inflammatory cytokines in normal renal 
function and CKD patients and precise usage of these 
agents is being evaluated in different trials around the 
world (74).
Conclusion
The new coronavirus (SARS-CoV2-) can cause kidney 
impairment. The exact mechanism of kidney involvement 
in COVID-19 infection has not been clarified yet. Until 
now, there is no specific medication for the cure of 
coronavirus; hence, the primary solution is supportive 
care such as preservation of vital signs, regulation of 
oxygen and blood pressure and reduction complications 
such as secondary infections or other failures of the organs 
of the body, including the kidney.
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